KRS Capital Management LLC Acquires 83 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

KRS Capital Management LLC raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,430 shares of the medical research company’s stock after buying an additional 83 shares during the quarter. KRS Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $831,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Northwest Financial Advisors bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. True Wealth Design LLC boosted its position in shares of Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 51 shares in the last quarter. Pineridge Advisors LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $39,000. Cape Investment Advisory Inc. raised its stake in Thermo Fisher Scientific by 52.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock valued at $40,000 after buying an additional 26 shares during the last quarter. Finally, Raleigh Capital Management Inc. raised its stake in Thermo Fisher Scientific by 49.1% during the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after buying an additional 27 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,238,340.48. The disclosure for this sale can be found here. Insiders sold a total of 22,000 shares of company stock valued at $12,532,780 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $552.72 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The firm has a market capitalization of $210.98 billion, a P/E ratio of 35.45, a P/E/G ratio of 2.57 and a beta of 0.79. The stock has a 50 day moving average price of $574.84 and a 200 day moving average price of $562.59.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The business had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Analysts Set New Price Targets

A number of research analysts have issued reports on TMO shares. Evercore ISI lifted their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. HSBC increased their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Barclays lowered their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday. Citigroup initiated coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Finally, Jefferies Financial Group restated a “buy” rating and issued a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $607.06.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.